Lee Cohen
Psychiatry · Hastings On Hudson, NYNPI 1174669683
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $596,062 of the $690,173 with a category attached, or 86.4%. 23 manufacturers reported payments, led by AbbVie at 54.0% of the total. 2025 is the largest year on record at $212,594, 2.2 times the $94,823 reported in 2019. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,082 payments — averaging $637.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$372K
- E.r. Squibb & Sons, L.L.C.$130K
- Ironshore Pharmaceuticals Inc.$54K
- Axsome Therapeutics, Inc.$46K
- Corium, LLC$34K
- Sunovion Pharmaceuticals Inc.$25K
- plus $29K from 17 others
Across 4 payments — averaging $82,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$329K
What the payments were for
- Consulting fees$46,8667%
- Speaking & faculty fees$596,06286%
- Travel & lodging$25,5224%
- Food & beverage$21,6153%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 592 | $372,361 |
| E.r. Squibb & Sons, L.L.C. | 156 | $129,537 |
| Ironshore Pharmaceuticals Inc. | 108 | $54,440 |
| Axsome Therapeutics, Inc. | 48 | $46,247 |
| Corium, LLC | 47 | $34,146 |
| Sunovion Pharmaceuticals Inc. | 54 | $24,920 |
| Tris Pharma Inc | 15 | $9,190 |
| Neurocrine Biosciences, Inc. | 17 | $8,230 |
| Supernus Pharmaceuticals, Inc. | 10 | $6,152 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $3,557 |
| Neos Therapeutics, LP | 4 | $753 |
| Johnson & Johnson | 5 | $144 |
| Otsuka America Pharmaceutical, Inc. | 6 | $128 |
| Lundbeck LLC | 2 | $116 |
| Sage Therapeutics, LLC | 1 | $59 |
| Vertical Pharmaceuticals, LLC | 2 | $38 |
| Shire North American Group Inc | 2 | $31 |
| Janssen Scientific Affairs, LLC | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$363,372
- COBENFY$80,000
- Auvelity$45,500
- Azstarys$33,496
- Jornay PM 20mg capsules (Bottle of 100)$26,912
- JORNAY PM$25,587
- LATUDA$23,377
- Quillichew ER$8,950
- Dyanavel XR$8,950
- INGREZZA$7,941
- Quillivant$5,150
- Quillivant XR$3,800
- CAPLYTA$3,500
- Adzenys XR-ODT$671
- Cotempla XR-ODT$671
- VIIBRYD$200
How this compares
$690,173 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RisperdalRisperidone | 11 | $4,155 |
| Fluvoxamine Maleate | 17 | $1,103 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $922 |
| Vilazodone Hcl | 12 | $736 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $620 |
| Lorazepam | 41 | $313 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $260 |
| Escitalopram Oxalate | 32 | $173 |
| Buspirone Hcl | 20 | $166 |
| Clonazepam | 14 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRisperdal | $144 | $4,15511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Hastings On Hudson
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.